Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

GSK (GSK.L)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (p) Price Target (p) Rating
2022-04-0416531680Neutral
2022-04-1117841790Neutral
2022-06-0616951866Neutral
2022-07-0817551876Neutral
2022-07-1917831850Neutral
2022-07-2917281860Neutral
2022-08-0516671820Neutral
2022-11-1113241300Sell
2023-01-0914211245Sell
2023-03-0114221300Sell
2023-05-0514621310Sell
2024-01-1515801860Buy
2024-03-1916642040Buy
2024-07-0815101580Neutral
2025-02-0614801600Neutral

Disclosures

  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.